Preservative-free, clear cyclosporine A solution in phase 2
for the treatment of moderate to severe dry eye disease

Novaliq Product CyclaSol

CyclASol® is a clear, preservative-free ophthalmic solution of cyclosporine A, formulated under clinical evaluation. It is an anti-inflammatory and immunomodulating drug for the treatment of dry eye disease (DED) with a demonstrated early onset of action and excellent tolerability.

Cyclosporine A has been proven to be the most successful API for the treatment of DED in the United States so far. In January 2017 Novaliq announced positive phase 2 results evaluating CyclASol® in 207 patients with moderate to severe DED.
The reported data confirmed that CyclASol® had demonstrated a superior outcome and an early onset of action when compared head to head with Restasis (Allergan plc, USA).

What is the regulatory status of CyclASol®?

CyclASol® is in clinical development with New Drug Applications filings anticipated in USA, Japan and Europe.



Torkildsen et al, 2017 901.44 KB 462 downloads

A Clinical Phase 2 Study to Assess Safety, Efficacy, and Tolerability of CyclASol®...

Are you interested in a collaborating with Novaliq?

Start typing and press Enter to search